Virtu Financial LLC Takes $1.99 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Virtu Financial LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,230 shares of the company’s stock, valued at approximately $1,985,000.

Other institutional investors have also added to or reduced their stakes in the company. Toronto Dominion Bank grew its position in shares of Neurocrine Biosciences by 32.8% in the 3rd quarter. Toronto Dominion Bank now owns 12,684 shares of the company’s stock worth $1,461,000 after buying an additional 3,131 shares during the period. Coldstream Capital Management Inc. grew its holdings in Neurocrine Biosciences by 15.2% in the third quarter. Coldstream Capital Management Inc. now owns 3,917 shares of the company’s stock worth $452,000 after purchasing an additional 516 shares during the period. Geode Capital Management LLC grew its holdings in Neurocrine Biosciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company’s stock worth $213,773,000 after purchasing an additional 39,610 shares during the period. Peloton Wealth Strategists bought a new position in shares of Neurocrine Biosciences during the third quarter valued at approximately $405,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Neurocrine Biosciences during the third quarter valued at approximately $3,662,000. Institutional investors own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Jefferies Financial Group increased their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Royal Bank of Canada cut their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Finally, BMO Capital Markets decreased their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $165.18.

Neurocrine Biosciences Stock Down 1.1 %

NASDAQ NBIX opened at $126.79 on Friday. The company has a 50-day moving average price of $121.49 and a 200-day moving average price of $130.78. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The firm has a market capitalization of $12.84 billion, a P/E ratio of 33.99 and a beta of 0.34.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.